BRIDGEWATER, N.J.--(BUSINESS WIRE)--CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, announces the receipt of a request for additional information and data, including six month stability data on the third and final test batch from TUV-SUD (the Testing and Certification Group) and MEB-Netherlands (the Competent Authority) on the CE Mark application for Neut...  Full Article  @ BusinessWire - 1 year ago